• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Rockwell Medical Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    5/20/25 4:13:55 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RMTI alert in real time by email
    false 0001041024 0001041024 2025-05-20 2025-05-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of

    the Securities Exchange Act of 1934

     

     

     

    Date of Report (Date of earliest event reported): May 20, 2025

     

    Rockwell Medical, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware 000-23661 38-3317208
    (State or other jurisdiction
    of incorporation)
    (Commission File Number) (IRS Employer
    Identification No.)

     

    30142 S. Wixom Road, Wixom, Michigan 48393

    (Address of principal executive offices, including zip code)

     

    (248) 960-9009

    (Registrant’s telephone number, including area code)

     

    N/A

    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
      
    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
      
    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
      
    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class  Trading  Symbol  Name of Each exchange on which
    registered
    Common Stock, par value $0.0001  RMTI  Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 5.07         Submission of Matters to a Vote of Security Holders.

     

    On May 20, 2025, Rockwell Medical, Inc. (the “Company”) held its 2025 Annual Meeting of the Stockholders (the "Annual Meeting"). The following matters were submitted to a vote of the stockholders at the Annual Meeting and the voting results were as follows:

     

    Proposal One: To elect the two Class I directors to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until his successor has been duly elected and qualified.

     

       For   Against   Abstain   Broker Non-Votes 
    John G. Cooper   14,278,753    615,440    36,816    8,372,386 
    Allen Nissenson, MD   14,396,057    500,966    33,986    8,372,386 
                         
    Proposal Two: To approve, on an advisory basis, the compensation of the Company's named executive officers.
     
    For  Against    Abstain    Broker Non-Votes     
    13,310,315   1,066,331    554,363    8,372,386     
                         
    Proposal Three: To ratify the selection of EisnerAmper LLP as the Company’s independent registered public accounting firm for 2025.
                         
    For  Against   Abstain                 
    21,767,571   361,807    1,174,017                 
                               
    Proposal Four: To approve an amendment and restatement of the Rockwell Medical, Inc. 2018 Long Term Incentive Plan to, among other things, increase the number of shares reserved for issuance thereunder by 5,000,000 shares.
                               
    For  Against    Abstain    Broker Non-Votes     
    12,862,271   2,013,968    54,770    8,372,386         

      

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      ROCKWELL MEDICAL, INC.
         
    Date: May 20, 2025 By:  /s/ Mark Strobeck
        Mark Strobeck
        Chief Executive Officer

     

     

     

    Get the next $RMTI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RMTI

    DatePrice TargetRatingAnalyst
    11/14/2024$5.00Buy
    Rodman & Renshaw
    1/18/2022$5.00 → $3.00Buy
    HC Wainwright & Co.
    9/7/2021$5.50 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $RMTI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rockwell Medical Announces First Quarter 2025 Results

      Reports net sales of $18.9 million for the first quarter of 2025, a 17% decrease from net sales of $22.7 million for the first quarter of 2024. Reports gross profit of $3.0 million for the first quarter of 2025, in line with the same period in 2024. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three months ended March 31, 2025. "During the first quarter, we continued to diversify our customer base with some of the leading regional, national and global hemodialysis provi

      5/12/25 6:00:00 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rockwell Medical to Release First Quarter 2025 Results on Monday, May 12, 2025

      Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the first quarter ended March 31, 2025 on Monday, May 12, 2025. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Monday, May 12, 2025 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.RockwellMed.com/Results Speakers:

      4/14/25 6:00:00 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rockwell Medical Announces Fourth Quarter and Full-Year 2024 Financial and Operational Results

      Achieves profitability on an adjusted EBITDA basis for the full-year 2024, the first time in the Company's history. Reports record gross profit for the third year in a row, generating $17.5 million in 2024, a 101% increase over 2023. Reports record net sales for the third year in a row, generating $101.5 million in 2024, a 21% increase over 2023. Net sales for the fourth quarter of 2024 were $24.7 million, a 12% increase over the same period in 2023. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and o

      3/20/25 6:00:00 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RMTI
    Leadership Updates

    Live Leadership Updates

    See more
    • Universal Display Corporation Announces the Appointment of New Board Members

      Universal Display Corporation (NASDAQ:OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today announced that Dr. Nigel Brown and Dr. Joan Lau have joined the Company's Board of Directors, effective March 4, 2024. The addition of these new directors expands UDC's Board to ten members. "I am pleased to welcome Nigel and Joan to the Board," said Steven V. Abramson, President and Chief Executive Officer of Universal Display Corporation and a member of the Board. "Nigel adds a wealth of business innovation, technical knowledge and corporate strategic planning expertise to our Board. Joan brings over two decades of extensive scienti

      3/7/24 4:05:00 PM ET
      $BDN
      $NOTV
      $OLED
      $RMTI
      Real Estate Investment Trusts
      Real Estate
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Rockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of Directors

      Brings more than 20 years of experience as an entrepreneur scientist, CEO, operator, investor, and board member of public and private biopharmaceutical companies Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joan Lau, Ph.D. to its board of directors. Dr. Lau's appointment increases Rockwell Medical's board of directors to seven members. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017906241/en/RMTI) (Photo: Business Wire)"

      10/17/23 6:00:00 AM ET
      $BDN
      $RMTI
      $RCOR
      Real Estate Investment Trusts
      Real Estate
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rockwell Medical, Inc. Appoints Mark Strobeck, Ph.D., as President and Chief Executive Officer

      WIXOM, Mich. , June 22, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (NASDAQ:RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that the Board of Directors has appointed Mark Strobeck, Ph.D., as President and Chief Executive Officer, effective July 1, 2022. Dr. Strobeck will also join the Company's Board of Directors. Russell Ellison, M.D., M.Sc., will be stepping down as President and Chief Executive Officer and as a member of the Company's Board of Directors effective June 30, 2022. "We are exci

      6/24/22 8:56:00 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RMTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Rockwell Medical Inc.

      SC 13G/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)

      11/14/24 5:17:40 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Rockwell Medical Inc. (Amendment)

      SC 13G/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)

      2/14/24 2:31:02 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Rockwell Medical Inc. (Amendment)

      SC 13D/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)

      9/6/23 4:49:44 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RMTI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Irrevocable Larson Family Investment Trust bought $94,018 worth of shares (87,500 units at $1.07), increasing direct ownership by 3% to 3,557,500 units (SEC Form 4)

      4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

      4/15/25 2:02:44 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RMTI
    SEC Filings

    See more
    • Rockwell Medical Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - ROCKWELL MEDICAL, INC. (0001041024) (Filer)

      5/20/25 4:13:55 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rockwell Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ROCKWELL MEDICAL, INC. (0001041024) (Filer)

      5/12/25 7:21:47 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Rockwell Medical Inc.

      10-Q - ROCKWELL MEDICAL, INC. (0001041024) (Filer)

      5/12/25 7:00:44 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RMTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lau Joan was granted 50,000 shares, increasing direct ownership by 79% to 113,111 units (SEC Form 4)

      4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

      5/21/25 7:10:30 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Cooper John G was granted 50,000 shares, increasing direct ownership by 52% to 145,451 units (SEC Form 4)

      4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

      5/21/25 7:08:46 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Nissenson Allen was granted 50,000 shares, increasing direct ownership by 54% to 142,597 units (SEC Form 4)

      4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

      5/21/25 7:07:20 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RMTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Rockwell Medical with a new price target

      Rodman & Renshaw initiated coverage of Rockwell Medical with a rating of Buy and set a new price target of $5.00

      11/14/24 7:56:29 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Rockwell Medical with a new price target

      HC Wainwright & Co. reiterated coverage of Rockwell Medical with a rating of Buy and set a new price target of $3.00 from $5.00 previously

      1/18/22 10:00:06 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Rockwell Medical with a new price target

      HC Wainwright & Co. reiterated coverage of Rockwell Medical with a rating of Buy and set a new price target of $5.00 from $5.50 previously

      9/7/21 6:17:47 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RMTI
    Financials

    Live finance-specific insights

    See more
    • Rockwell Medical Announces First Quarter 2025 Results

      Reports net sales of $18.9 million for the first quarter of 2025, a 17% decrease from net sales of $22.7 million for the first quarter of 2024. Reports gross profit of $3.0 million for the first quarter of 2025, in line with the same period in 2024. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three months ended March 31, 2025. "During the first quarter, we continued to diversify our customer base with some of the leading regional, national and global hemodialysis provi

      5/12/25 6:00:00 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rockwell Medical to Release First Quarter 2025 Results on Monday, May 12, 2025

      Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the first quarter ended March 31, 2025 on Monday, May 12, 2025. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Monday, May 12, 2025 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.RockwellMed.com/Results Speakers:

      4/14/25 6:00:00 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rockwell Medical Announces Fourth Quarter and Full-Year 2024 Financial and Operational Results

      Achieves profitability on an adjusted EBITDA basis for the full-year 2024, the first time in the Company's history. Reports record gross profit for the third year in a row, generating $17.5 million in 2024, a 101% increase over 2023. Reports record net sales for the third year in a row, generating $101.5 million in 2024, a 21% increase over 2023. Net sales for the fourth quarter of 2024 were $24.7 million, a 12% increase over the same period in 2023. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and o

      3/20/25 6:00:00 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care